WINDSOR, ON / ACCESSWIRE / March 17, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce a Company mentioned in last week's update has surged amidst growing Investor interest.

Many factors may have been attributed to the enormous move in Propanc Health Group (PPCH), but traders acting early after the feature piece could have turned $9,000 into $100,000. The Company's update in the form of a press release the next day added fuel to the fire; but many Traders are speculating that this ticker has a large short position. We feel if the chart breaks above the previous high of $0.042, after this well deserved break, the technicals (short covering, chart readers) could drive prices towards the $0.10 level. The chart looks extremely poised to jump.

Undoubtedly many eyes are on the Biotech sector and that could have been another contributing factor to the interest. And more specifically, the oncology (cancer) focused Companies have the most cheerleaders. Most Retail traders do not yet know of the awesome science milestones cancer therapies have made over the past 2 or 3 years-these new retail traders should power the sector for the foreseeable future. Futuristic treatments "ideas" that were talked about at dinner parties in the 80's and 90's are now a reality.

The Wealth Biotech Trader encourages all readers to watch "Killing Cancer," a recent HBO special. Click here to watch: http://goo.gl/BMr1Ju . The Chief Investment Officer of Google Ventures, Googles Venture Capital Investment arm (a fund with a significant stake in a myriad of Biotech Companies), said it best in a recent Bloomberg article: "You can now legitimately invest in a company that can cure cancer."

In addition to Propanc (PPCH), in the last release we mentioned some other notable names (Stemline Therapeutics, Inc. (STML), Verastem, Inc. (VSTM), CTI BioPharma Corp. (CTIC). All of these companies have a novel approach to treatment of cancer which hopefully will result in the elimination of radiation therapy and chemotherapy in the not too distant future.

Propanc Health Group (PPCH) should be closely watched over the coming days, weeks and months to see how news from their recently announced R&D program unfolds. The Wealthy Biotech Trader will bring these updates to readers with a break-down of the technical and scientific jargon along with updates on the fundamentals of the Company.

The Wealthy Biotech Trader is researching several new trade ideas which have the makings for large market moves such as the one Propanc Health Group has undergone. Active traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through our Twitter and Facebook accounts, as well as newswire.

TO GET BREAKING NEWS FROM US:

Like us on Facebook: www.facebook.com/WealthyVC

Join our Facebook group: www.facebook.com/groups/TheWealthyVentureCapitalist

Follow us on Twitter: www.twitter.com/Wealthy_VC

FOR FURTHER INFORMATION PLEASE CONTACT US AT:

Toll Free: 1 (866) - 950-8300

Email: TheWealthyVentureCapitalist@Gmail.com

-------------------------------------------

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.

The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice.

The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Further, The Wealthy Biotech Trader has no advance knowledge of any future events of the profiled companies which includes, but is not limited to, news & press releases, changes in corporate structure, or changes in share structure.

Our website and newsletter are for Entertainment purposes only. This newsletter is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.

Release of Liability: Through use of this email and/or website advertisement viewing or using you agree to hold The Wealthy Biotech Trader, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The Wealthy Biotech Trader sponsored advertisements do not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by The Wealthy Biotech Trader or an offer or solicitation to buy or sell any security.

COMPENSATION: The Wealthy Biotech Trader has been compensated four thousand dollars cash via bank wire by Propanc Health Group Inc. (PPCH) for a 1 month Investor Relations Contract. The Wealthy Biotech Trader does not own any shares of PPCH. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.

None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead The Wealthy Biotech Trader strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. The Wealthy Biotech Trader further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects," "foresee," "expects," "will," "anticipates," "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could," or "might" occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security's previous day closing price and the high of day price during our promotional coverage.

In preparing this publication, The Wealthy Biotech Trader has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, The Wealthy Biotech Trader and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. The Wealthy Biotech Trader is not responsible for any claims made by the companies advertised herein, nor is The Wealthy Biotech Trader responsible for any other promotional firm, its program or its structure.

SOURCE: The Wealthy Biotech Trader